Skip to main content
Clinical Trials/CTRI/2021/10/037378
CTRI/2021/10/037378
Completed
Phase 2

A Study To Assess Efficacy And Safety Of Polyherbal Formulation (COVI-RB01) As An Add-On Therapy With Standard of Care In Mild And Moderate Covid-19 Positive Patients - COVI-RB01

Alakart Bio Pharma Pvt Ltd0 sites130 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Sponsor
Alakart Bio Pharma Pvt Ltd
Enrollment
130
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
January 27, 2022
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Alakart Bio Pharma Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • RT\-PCR based diagnosis of COVID\-19
  • \- Treatment trials: cases of mild and moderate severity.
  • \- Willingness to participate.

Exclusion Criteria

  • \- Severe category (Spo2 \< 90\).
  • \- Individuals with uncontrolled, unstable co\-morbidities.
  • \- Individuals with pre\-existing respiratory conditions. Immuno\-compromised individuals or those on immuno\-suppressants.
  • \- Pregnant and lactating females.

Outcomes

Primary Outcomes

Not specified

Similar Trials